Outlook Therapeutics (OTLK) Operating Leases (2019 - 2026)
Outlook Therapeutics (OTLK) reported Operating Leases of $156958.0 for Q1 2026, down 28.32% year-over-year from $218961.0 in Q1 2025, and down 8.74% quarter-over-quarter from $171988.0 in Q4 2025.
Outlook Therapeutics (OTLK) Operating Leases (2019 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 8 years of Operating Leases data on file, last reported at $156958.0 in Q1 2026.
- Operating Leases for Q1 2026 came in at $156958.0, down 28.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $156958.0 (down 28.32% YoY), and the FY2025 annual result was $188801.0, down 23.54% from the prior year.
- Operating Leases retreated to $156958.0 in Q1 2026 per OTLK's latest filing, from $171988.0 in the prior quarter.
- Over five years, Operating Leases peaked at $260395.0 in Q2 2024 and troughed at $3929.0 in Q1 2023.
- A 5-year average of $139621.8 and a median of $171988.0 in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2023: Operating Leases changed 0.0% in 2022, then sank 92.0% in 2023.
- A 5-year view of Operating Leases shows it stood at $15573.0 in 2022, then plunged by 74.77% to $3929.0 in 2023, then surged by 5833.14% to $233113.0 in 2024, then declined by 26.22% to $171988.0 in 2025, then retreated by 8.74% to $156958.0 in 2026.
- Business Quant data shows OTLK's Operating Leases at $156958.0 in Q1 2026, $171988.0 in Q4 2025, and $188801.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156,958.00 |
| Dec 31, 2025 | 171,988.00 |
| Sep 30, 2025 | 188,801.00 |
| Jun 30, 2025 | 204,145.00 |
| Mar 31, 2025 | 218,961.00 |
| Dec 31, 2024 | 233,113.00 |
| Sep 30, 2024 | 246,922.00 |
| Jun 30, 2024 | 260,395.00 |
| Mar 31, 2023 | 3,929.00 |
| Dec 31, 2022 | 15,573.00 |
| Sep 30, 2022 | 26,995.00 |
| Jun 30, 2022 | 38,203.00 |
| Mar 31, 2022 | 49,100.00 |
| Dec 31, 2021 | 15,573.00 |
| Sep 30, 2021 | 26,995.00 |
| Jun 30, 2021 | 79,923.00 |
| Sep 30, 2020 | 187,486.00 |
| Jun 30, 2020 | 48,394.00 |
| Mar 31, 2020 | 95,747.00 |
| Dec 31, 2019 | 142,129.00 |